(Total Views: 339)
Posted On: 07/10/2020 10:19:24 AM
Post# of 72
Cont'd from Christopher Reinhard:
"I have sent along a few slides to provide a bit more insight into our efforts, and to discuss the many challenges covering developing ‘anti-anginal’ therapies. In the last fifty years, the FDA has approved only one anti-anginal drug with a new mechanism of action -- Ranexa (ranolazine). The FDA approval of anti-anginal medications have few and far between. As outlined in the first chart above, the clinical development for Ranexa began was initiated by Snytex Corp. in 1985, and then it was sold to Roche and years later it was acquired by CV Therapeutics. Over 21 year development, after multiple clinical failures and economic setbacks and challenges, Ranexa was finally approved by the FDA in 2006. a 21 years of development. Following FDA approval, a few years later, CV was acquired by Gilead Sciences for $1.4 billion."
"I have sent along a few slides to provide a bit more insight into our efforts, and to discuss the many challenges covering developing ‘anti-anginal’ therapies. In the last fifty years, the FDA has approved only one anti-anginal drug with a new mechanism of action -- Ranexa (ranolazine). The FDA approval of anti-anginal medications have few and far between. As outlined in the first chart above, the clinical development for Ranexa began was initiated by Snytex Corp. in 1985, and then it was sold to Roche and years later it was acquired by CV Therapeutics. Over 21 year development, after multiple clinical failures and economic setbacks and challenges, Ranexa was finally approved by the FDA in 2006. a 21 years of development. Following FDA approval, a few years later, CV was acquired by Gilead Sciences for $1.4 billion."
(0)
(0)
